ClinicalTrials.gg
RecruitingNCT07672392EXERCISE DIEPUpdated Jun 26, 2026

The Effect of a Post-operative Exercise Programme Versus Standard Care on Physical Fitness of Patients With Breast Cancer Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Reconstruction Surgery

An interventional study of Structured individualised 12-week post operative exercise programme in Breast Cancer and Exercise, sponsored by Royal College of Surgeons, Ireland. Recruiting at 1 site in Ireland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Royal College of Surgeons, Ireland · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Aug 2024, registered Feb 2026).
  • Started Aug 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

All patients undergoing mastectomy for breast cancer should be offered the option of reconstructive surgery. The Deep Inferior Epigastric Perforator Flap or DIEP reconstruction as it is commonly referred to, is becoming the favoured reconstruction by both patients and surgeons as it gives a great cosmetic outcome as well as being a good option for patients who may have to undergo radiotherapy treatment after their surgery.

Exercise has been demonstrated in previous research to improve tolerance of treatment (particularly chemotherapy), post operative fatigue and the overall quality of life in patients undergoing cancer treatment. Furthermore, it has shown to improve survival in patients who are being treated for breast cancer. The investigators are undertaking this study to investigate whether a structured exercise programme will improve patients fitness after surgery and ultimately improve their recovery after their reconstructive surgery. To do this, half of the people taking part will be undertaking a structured exercise programme and the other half will not and will be assessing which group recover better after their surgery. Currently, no breast reconstruction patients in Ireland are receiving a formal "exercise prescription" after their surgery so will be looking to see if this helps people recover better before it is made standard care for every breast patient in Ireland.

Read the detailed description

Primary Objective:

To evaluate the impact of a structured, post-operative exercise programme on patient-reported and functional outcomes following DIEP flap breast reconstruction.

Secondary Objectives:

  • To examine the effects of the exercise programme on upper and lower limb strength, body composition (BMI, fat and muscle mass, bone density), and functional recovery.
  • To evaluate the influence of exercise on post-operative complication rates, length of hospital stay and time to return to daily activities.
  • To explore changes in psychological health and body image perception using validated questionnaires.
  • To assess adherence, feasibility, and safety of the structured exercise programme within a breast reconstruction population.
  • To perform an exploratory health-economic analysis comparing the costs and potential healthcare savings associated with the intervention versus standard care.
02

Conditions studied

  • Breast Cancer
  • Exercise

Keywords

  • Breast cancer
  • DIEP Reconstruction
  • Exercise
03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 78 is close to the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Royal College of Surgeons, Ireland is the lead sponsor of 93 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 years and older
  2. Candidates who have already been selected to undergo mastectomy and reconstruction by the breast MDT for the following indications:

    1. Genetic mutation carriers undergoing risk-reducing mastectomy.
    2. Ductal carcinoma in situ (DCIS) requiring mastectomy.
    3. Early invasive breast cancer requiring mastectomy.
    4. The tumour must not have skin involvement and no evidence of invasive disease within 1cm of skin, nipple or pectoralis major muscle (as proven on MRI).
  3. Candidates for breast reconstruction with DIEP.
  4. Fluent in English
  5. Fit for general anaesthetic Signed form

Exclusion criteria

Exclusion Criteria:

  1. Advanced breast cancer with skin involvement.
  2. Undergoing bilateral DIEP reconstruction or other forms of breast reconstruction (e.g., TRAM, implant-based, LD flap).
  3. Pregnancy
  4. Lactation Patients with insufficient English to sign an (i.e. interpreter required).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Intervention

    Structured individualised 12-week post operative exercise programme based on ACSM oncology guidelines, incorporating aerobic, resistance and flexibility training delivered in person or via zoom.

    Behavioral: Structured individualised 12-week post operative exercise programme

  • No intervention
    Control

    standard post-operative care

Interventions

  • BehavioralStructured individualised 12-week post operative exercise programme

    Structured individualised 12-week post operative exercise programme based on ACSM oncology guidelines, incorporating aerobic, resistance and flexibility training delivered in person or via zoom.

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory Fitness

    Cardiorespiratory fitness measured using the 6-Minute Walk Test (6MWT). Outcome reported as change in distance walked (metres) from baseline to 6 months post-operatively. Greater distance indicates improved cardiorespiratory fitness.

    Time frame: Measured at baseline (recruitment), 6 months postoperatively and at 1 year postoperatively

Secondary outcomes

  1. Hand Grip Strength

    Measured using a hand dynamometer and reported in kilograms.

    Time frame: 6 months and 12 months post operatively

  2. Body Mass Index

    Body mass index (BMI) calculated from measured weight and height and reported in kilograms per square meter (kg/m²).

    Time frame: At six months and 12 months postoperatively

  3. EQ5D5L Health Related Quality of Life

    Quality of Life and Psychosocial Health: Assessed using the BREAST-Q (psychosocial and sexual well-being domains)

    Time frame: At 6 months and 12 months post operatively

  4. Percentage Body Fat

    Percentage body fat measured using bioelectrical impedance analysis with a Tanita device and reported as percentage body fat (%).

    Time frame: At 6 months and 12 months postoperatively

  5. Muscle Mass

    Muscle mass measured using bioelectrical impedance analysis with a Tanita device and reported in kilograms (kg).

    Time frame: At 6 months and 12 months postoperatively

  6. Bone Mass

    Bone mass measured using bioelectrical impedance analysis with a Tanita device and reported in kilograms (kg).

    Time frame: At 6 months and 12 months postoperatively

  7. Lower Limb Strength

    Measured using the 30 second Sit to Stand Test

    Time frame: Measured at 6 months and 1 year postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared as this could potentially identify participants. Anonymous datasets will be available for validation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 40 months is above that.

Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Jun 26, 2026
StartActual
Aug 1, 2024
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2028
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07672392
Lead sponsor
Royal College of Surgeons, Ireland
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Aug 1, 2024
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Jun 26, 2026

Study contacts

Arnold Hill, MB, BCh, BAO, MCh, FRCSI
Contact
adkhill@rcsi.com
+35318093000
Aisling Hegarty, PhD
Contact
Aislinghegarty@rcsi.ie
018093000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion